Female reproductive system neoplasm
MONDO:0021148A benign, precancerous, or malignant neoplasm that affects the female reproductive system. Representative examples include uterine corpus leiomyoma, endocervical polyp, ovarian carcinoma, cervical carcinoma, and endometrial carcinoma.
Also known as: female reproductive organ neoplasm (disease), female reproductive organ tumor, female reproductive organ tumour, female reproductive system neoplasm, female reproductive system neoplasm (disease), female reproductive system tumor, female reproductive system tumour, gynecologic neoplasm
3680 clinical trials for this condition and its sub-types, 27 tagged with Female reproductive system neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Female reproductive system neoplasm
-
Female reproductive organ cancer 245 trials · 2,252 incl. sub-types
9 sub-types
- Uterine cancer 95 trials · 1,261 incl. sub-types Sub-types →
- Ovarian cancer 1,002 trials · 1,198 incl. sub-types Sub-types →
- Fallopian tube cancer 298 trials · 408 incl. sub-types Sub-types →
- Endometrioid adenocarcinoma 12 trials · 144 incl. sub-types Sub-types →
- Vulva cancer 88 trials · 102 incl. sub-types Sub-types →
- Vaginal cancer 53 trials · 60 incl. sub-types Sub-types →
- Adenosarcoma 0 trials · 2 incl. sub-types Sub-types →
- Gestational choriocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Adenocarcinofibroma 0 trials Sub-types →
-
Tumor of uterus 10 trials · 1,432 incl. sub-types
6 sub-types
- Uterine cancer 95 trials · 1,261 incl. sub-types Sub-types →
- Uterine cervix neoplasm 39 trials · 731 incl. sub-types Sub-types →
- Endometrium neoplasm 478 trials · 687 incl. sub-types Sub-types →
- Corpus uteri neoplasm 1 trial · 191 incl. sub-types Sub-types →
- Uterine benign neoplasm 3 trials · 112 incl. sub-types Sub-types →
- Placenta neoplasm 0 trials · 6 incl. sub-types Sub-types →
-
Ovarian neoplasm 78 trials · 1,213 incl. sub-types
8 sub-types
- Ovarian cancer 1,002 trials · 1,198 incl. sub-types Sub-types →
- Ovarian epithelial tumor 14 trials · 664 incl. sub-types Sub-types →
- Ovarian germ cell tumor 9 trials · 13 incl. sub-types Sub-types →
- Ovarian sex cord-stromal tumor 1 trial · 7 incl. sub-types Sub-types →
- Ovarian benign neoplasm 1 trial Sub-types →
- Ovarian endometrioid stromal and related neoplasms 0 trials
- Ovarian melanoma 0 trials
- Rete ovarii neoplasm 0 trials Sub-types →
-
Fallopian tube neoplasm 199 trials · 417 incl. sub-types
5 sub-types
- Fallopian tube cancer 298 trials · 408 incl. sub-types Sub-types →
- Fallopian tube mucinous tumor 1 trial · 10 incl. sub-types Sub-types →
- Fallopian tube endometrioid tumor 3 trials
- Fallopian tube benign neoplasm 0 trials Sub-types →
- Fallopian tube germ cell tumor 0 trials Sub-types →
-
Benign female reproductive system neoplasm 5 trials · 117 incl. sub-types
7 sub-types
- Uterine benign neoplasm 3 trials · 112 incl. sub-types Sub-types →
- Adenomyoma 1 trial · 3 incl. sub-types Sub-types →
- Ovarian benign neoplasm 1 trial Sub-types →
- Adenofibroma 0 trials Sub-types →
- Benign vaginal neoplasm 0 trials Sub-types →
- Fallopian tube benign neoplasm 0 trials Sub-types →
- Vulvar benign neoplasm 0 trials Sub-types →
-
Vulvar neoplasm 6 trials · 107 incl. sub-types
9 sub-types
- Vulva cancer 88 trials · 102 incl. sub-types Sub-types →
- Vulvar squamous neoplasm 0 trials · 28 incl. sub-types Sub-types →
- Vulvar glandular neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Bartholin gland neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Clitoris neoplasm 0 trials Sub-types →
- Germ cell tumor of the vulva 0 trials Sub-types →
- Paraurethral gland neoplasm 0 trials Sub-types →
- Vulvar benign neoplasm 0 trials Sub-types →
- Vulvar granular cell tumor 0 trials
-
Endometrioid tumor 1 trial · 89 incl. sub-types
1 sub-type
- Ovarian endometrial cancer 4 trials · 88 incl. sub-types Sub-types →
-
Vaginal neoplasm 2 trials · 61 incl. sub-types
7 sub-types
- Vaginal cancer 53 trials · 60 incl. sub-types Sub-types →
- Vaginal squamous tumor 0 trials · 8 incl. sub-types Sub-types →
- Vaginal glandular neoplasm 0 trials · 7 incl. sub-types Sub-types →
- Vaginal melanoma 1 trial
- Benign vaginal neoplasm 0 trials Sub-types →
- Endometrioid stromal and related neoplasms of the vagina 0 trials Sub-types →
- Extraovarian Brenner tumor of the vagina 0 trials
-
Gestational trophoblastic neoplasm 7 trials · 8 incl. sub-types
6 sub-types
- Gestational choriocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Hydatidiform mole, recurrent, 1 1 trial
- Epithelioid trophoblastic tumor 0 trials
- Hydatidiform mole, recurrent, 2 0 trials
- Invasive hydatidiform mole 0 trials
- Placental site trophoblastic tumor 0 trials
-
2 sub-types
-
1 sub-type
Most studied deeper sub-types
Showing the 400 most recently updated of 446 trials in this tab.
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Can a pill restore the Body's tumor suppressor to fight multiple cancers?
Cure Not yet recruitingThis trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…
Phase 1/2 • Sponsor: LG Chem • Aim: Cure
Last updated Aug 09, 2026 00:00 UTC
-
Could a blast of argon plasma wipe out cervical precancer without surgery?
Cure Not yet recruitingThis trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…
Sponsor: University Hospital Tuebingen • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
Can an immunotherapy drug replace surgery for some endometrial cancers?
Cure Not yet recruitingThis phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…
Phase 2 • Sponsor: Wang Jianliu • Aim: Cure
Last updated Jul 30, 2026 00:00 UTC
-
Can a Patient's own immune cells be supercharged to fight ovarian cancer?
Cure Not yet recruitingThis trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. Af…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Custom-Made cancer vaccine enters early human testing
Vaccine Not yet recruitingThis study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …
Early phase 1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
Disease control Not yet recruitingResearchers are testing whether a combination of semaglutide (Wegovy), a levonorgestrel-releasing intrauterine device (LNG-IUD), and a structured weight loss program can treat endometrial atypical hyperplasia or early-stage, grade 1 endometrioid endometrial cancer in women who wa…
Phase 2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Antibody-Drug conjugate takes aim at relapsed ovarian cancer
Disease control Not yet recruitingResearchers are testing whether torvutatug samrotecan, alone or with bevacizumab, works better than standard care as maintenance therapy for people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer. The trial enrolls about 600 participants who…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a targeted drug keep ovarian cancer at bay longer?
Disease control Not yet recruitingThis trial is testing whether a targeted therapy called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. Participants have already completed first-line platinum-…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a common cholesterol pill help chemotherapy fight ovarian cancer?
Disease control Not yet recruitingResearchers are studying whether adding daily atorvastatin to standard chemotherapy and surgery changes the immune cells inside advanced high grade serous tumors of the ovary, fallopian tube, or peritoneum. The trial enrolls 40 adults with Stage III or IV disease who cannot have …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new drug combo keep ovarian cancer from coming back?
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called BG-C9074 to bevacizumab helps adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has not worsened after initial platinum-based chemotherapy plus bevacizumab. Participants r…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Immunotherapy added to chemo aims to boost cervical cancer remission
Disease control Not yet recruitingResearchers are testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy before and after surgery can improve outcomes for people with locally advanced cervical cancer. About 35 participants will receive three cycles of adebrelimab plus paclitaxel and ci…
Phase 2 • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Weight-Loss drug meets hormonal IUD in hunt for Surgery-Free cancer care
Disease control Not yet recruitingResearchers are testing whether adding tirzepatide, a weekly drug that treats obesity and diabetes, to a standard levonorgestrel-releasing intrauterine device can help clear early endometrial cancer or a precancerous condition called endometrial intraepithelial neoplasia. The stu…
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a guided missile for chemo hit tumors harder and spare healthy tissue?
Disease control Not yet recruitingResearchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…
Phase 1 • Sponsor: TwoStep Therapeutics, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a Dual-Target drug crack resistant gynecologic and breast cancers?
Disease control Not yet recruitingResearchers are testing an oral drug called AL58805, which blocks two cancer-growth proteins, PI3K and mTOR, in adults with advanced endometrial, cervical, soft tissue sarcoma, or breast cancers that have worsened after at least one standard treatment. Participants receive AL5880…
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an oral drug that starves tumors help Hard-to-Treat cancers?
Disease control Not yet recruitingResearchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new drug extend remission in advanced ovarian cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called INCB123667 to the standard maintenance therapy bevacizumab can delay cancer recurrence in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants must have completed initial chemotherapy …
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shrink tumors that resist standard care?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…
Phase 1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smart drug shrink rare gynecologic tumors?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with advanced or metastatic squamous cell carcinoma of the vagina or vulva. These cancers are rare, and there is no standard second-line treatment. Sac-TMT is an antibody-drug conjugat…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to slow advanced cervical cancer
Disease control Not yet recruitingThis study tests whether adding a glutaminase inhibitor (telaglenastat) to standard chemoradiation helps people with advanced cervical cancer live longer without the disease getting worse. About 42 adults with stage III–IVA cervical cancer will receive the drug alongside standard…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can adding immunotherapy to standard cancer care be safe for indian patients?
Disease control Not yet recruitingThis trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…
Phase 4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in ovarian cancer
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
At-Home HPV tests could save lives of women with HIV
Disease control Not yet recruitingThis study looks at whether giving women living with HIV the option to collect their own HPV test samples at home or in their community, with help from health workers, increases how many get screened for cervical cancer. About 17,700 women will take part across multiple clinics. …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThis trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug outperform chemotherapy in Hard-to-Treat cervical cancer?
Disease control Not yet recruitingThis trial compares an experimental drug called JSKN033 with standard chemotherapy in people whose cervical cancer has returned or spread and no longer responds to platinum-based chemotherapy or PD-1/L1 inhibitors. The study includes about 368 adults with recurrent or metastatic …
Phase 3 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat gynecological tumors?
Disease control Not yet recruitingThis phase Ib/II trial tests an investigational drug called BL-M08D1 in adults with recurrent or metastatic gynecological cancers and other solid tumors. The study aims to find the safest and most effective dose and to see whether the drug can shrink tumors. Participants receive …
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can Long-Term tucatinib use remain safe for HER2-Positive cancers?
Disease control Not yet recruitingThis study offers continued access to tucatinib, an oral targeted therapy, for people with HER2-positive cancers (including breast, cervical, and lung) who were already benefiting from the drug in a previous Pfizer-sponsored trial. The main goal is to monitor long-term safety and…
Phase 4 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a pill target cancers with a specific gene flaw?
Disease control Not yet recruitingThis phase II trial tests an experimental drug called TR115 in people with advanced solid tumors that have a mutation in the ARID1A gene. The study includes patients with platinum-resistant ovarian clear cell carcinoma, endometrial cancer that failed immunotherapy, and other tumo…
Phase 2 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cream after heat treatment may help women with HIV beat HPV
Disease control Not yet recruitingThis study tests whether a self-applied cream (5-fluorouracil) after a heat procedure (thermal ablation) can clear HPV better than a placebo cream in 140 women with HIV in Kenya. Participants will use the cream every two weeks for 24 weeks and be followed for 48 weeks total. The …
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a new injection shrink advanced solid tumors?
Disease control Not yet recruitingThis phase 1/2 trial tests an investigational drug called HY07121, given as a subcutaneous injection, in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study has two parts: the first finds a safe dos…
Phase 1/2 • Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Long-Acting immune booster help fight advanced solid tumours?
Disease control Not yet recruitingThis early-phase trial is testing an investigational drug called FL115 in adults with advanced solid tumours that have progressed after standard therapy or for whom no standard treatment exists. FL115 is designed to stimulate the immune system's natural killer cells and T cells t…
Phase 1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat gynecological tumors?
Disease control Not yet recruitingThis phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Experimental virus therapy takes on Drug-Resistant cancers
Disease control Not yet recruitingThis early-stage trial tests a new cancer treatment called OTS-412, a modified virus designed to attack tumor cells. It is given alone or with hydroxyurea and the immunotherapy atezolizumab. The study includes 24 adults with advanced solid tumors that no longer respond to standar…
Phase 1 • Sponsor: Bionoxx Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new pill outsmart mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…
Phase 1 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat solid tumors
Disease control Not yet recruitingThis trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Dual-Action antibody outsmart advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SI-B036, a bispecific antibody designed to target cancer cells in a unique way. The study will enroll about 30 adults with locally advanced or metastatic gynecological tumors or other solid tumors. The main goals are t…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Weight-loss shot plus IUD may help reverse womb cancer without surgery
Disease control Not yet recruitingThis phase 2 trial tests whether adding tirzepatide (a weight-loss injection) to a levonorgestrel intrauterine device (LNG-IUD) can eliminate precancerous or early-stage endometrial cancer in overweight or obese women. About 55 women who want to avoid hysterectomy will receive bo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Not yet recruitingThis study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can immune cells shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether infusions of natural killer (NK) cells—a type of immune cell from a healthy donor—can safely help people with advanced solid tumors that have not responded to standard treatments. The study enrolls about nine adults aged 18 to 75 and uses…
Phase 1 • Sponsor: BOE Technology Group Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn childhood cancers
Disease control Not yet recruitingThis study tests a new treatment using a patient's own immune cells, modified to recognize and attack a protein called GD2 found on many solid tumors. The trial includes 100 people aged 1 to 65 with tumors that have not responded to standard therapy. The goal is to see if these m…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a novel radiation pattern boost cervical cancer control?
Disease control Not yet recruitingThis trial investigates whether adding a special radiation technique called spatially fractionated radiation therapy (SFRT) to standard chemoradiation can improve outcomes for people with locally advanced cervical cancer. Participants with stage IIB to IVA disease will be randoml…
Sponsor: The University of Hong Kong-Shenzhen Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Weight-Loss drug boost Fertility-Sparing cancer treatment?
Disease control Not yet recruitingThis trial tests whether adding mazdutide, a weekly injection that helps with weight loss, to a hormonal intrauterine device (IUD) can improve treatment for overweight or obese women with atypical endometrial hyperplasia or early-stage endometrioid endometrial cancer who wish to …
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Dual-Antibody combo hold ovarian cancer at bay longer?
Disease control Not yet recruitingThis trial is testing whether adding trastuzumab to the standard maintenance drug bevacizumab can delay cancer progression in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants who have completed initial chemotherapy plus bevacizumab without …
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Dual-Payload 'Smart Bomb' outsmart advanced ovarian cancer?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called TJ102 in people with advanced or metastatic ovarian cancer and other solid tumors that have stopped responding to standard treatments. TJ102 is a type of targeted therapy called an antibody-drug conjugate, designed …
Phase 1/2 • Sponsor: Phrontline Biopharma • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a targeted drug combo outsmart returning ovarian cancer?
Disease control Not yet recruitingThis phase II trial is testing whether a new drug, trastuzumab rezetecan, combined with carboplatin (and sometimes bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer. Participants will be randomly assigned to receive either this experimental combination…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can focused radiation boost Immunotherapy's power against advanced cancer?
Disease control Not yet recruitingThis phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…
Phase 2 • Sponsor: Mark Bernard • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can an amino acid boost the power of ovarian cancer treatment?
Disease control Not yet recruitingThis phase 1 trial is testing whether adding arginine, a common amino acid, to standard chemotherapy and immunotherapy can help people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. The study includes about 24 adults whose cancer has stopped responding to …
Phase 1 • Sponsor: Rebecca Arend • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New cream could fight HPV lesions in HIV patients
Disease control Not yet recruitingThis early-stage trial tests a topical ointment called ACU-D1 for HPV-related vulvar and perianal lesions in people with HIV. Nine participants will apply the cream twice daily for 4 weeks. The main goal is to find the safest dose and see if the treatment can boost immune markers…
Phase 1 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Could a dye given days before surgery help doctors spot hidden tumors?
Disease control Not yet recruitingThis study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…
Phase 4 • Sponsor: On Target Laboratories, LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…
Phase 1/2 • Sponsor: Antares Therapeutics, Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a new injection shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…
Phase 1/2 • Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Double-Wall bag stop leaks during keyhole fibroid surgery?
Disease control Not yet recruitingThis trial tests whether the LapBox Manual Containment System, a double-wall bag used during laparoscopic surgery, can prevent leaks when removing uterine fibroids. About 30 women having laparoscopic hysterectomy or myomectomy will use the device, and surgeons will check for any …
Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for Hard-to-Treat endometrial cancer: pfizer launches phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their ca…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Hormone-Blocking drug boost chemo against cervical cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a One-Two punch shrink fibroids better?
Disease control Not yet recruitingThis trial tests whether adding a chemical injection to microwave ablation improves treatment for uterine fibroids, common non-cancerous tumors that can cause heavy bleeding and pain. Microwave ablation uses heat to destroy fibroid tissue, but blood flow can cool the area and red…
Sponsor: Peking University Aerospace Center Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…
Phase 1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Old drug, new hope: mercaptopurine tested against rare cancer syndrome
Disease control Not yet recruitingThis trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a single injection curb blood loss in fibroid surgery?
Disease control Not yet recruitingThis trial tests whether injecting a diluted solution of terlipressin, a drug that narrows blood vessels, under the outer layer of a uterine fibroid before removal can reduce blood loss during myomectomy surgery. Women scheduled for myomectomy will be randomly assigned to receive…
Sponsor: Sevil Cankaya • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Drug combo keep fighting a rare ovarian cancer?
Disease control Not yet recruitingThis study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a smart drug deliver a lethal payload to endometrial cancer?
Disease control Not yet recruitingThis study tests an experimental drug called TUB-040 in people with recurrent or progressive endometrial cancer that has not responded to platinum-based chemotherapy and immunotherapy. TUB-040 is an antibody-drug conjugate designed to bind to a protein called NaPi2B on cancer cel…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart resistant ovarian cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two drugs—mirvetuximab soravtansine and suvemcitug—can help people with a type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The study will enroll 20 adults with FRα-positive, platinum-resistant recur…
Phase 2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a natural compound boost chemotherapy against endometrial cancer?
Disease control Not yet recruitingThis trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…
Phase 2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can an experimental pill boost chemotherapy's power against stubborn uterine cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an experimental drug called OK-1 to the standard chemotherapy paclitaxel can shrink tumors in people with advanced or recurrent endometrial cancer. Participants take OK-1 capsules twice daily along with weekly intravenous paclitaxel. T…
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
Disease control Not yet recruitingThis study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…
Sponsor: NING LI-GYN • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a nanoparticle deliver chemo more safely to Hard-to-Treat cancers?
Disease control Not yet recruitingThis trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…
Phase 1/2 • Sponsor: BrYet US, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
Disease control Not yet recruitingThis trial tests whether an online, personalized lifestyle program can help rural postmenopausal breast and endometrial cancer survivors lose weight and improve their health. Participants follow a tailored diet and aerobic exercise plan, with mobile health tools to track progress…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
A drug that may curb bleeding during fibroid surgery faces its first big test
Disease control Not yet recruitingThis trial tests whether a single injection of carbetocin, a longer-acting relative of oxytocin, can reduce blood loss in women undergoing open abdominal surgery to remove uterine fibroids. About 900 participants will be randomly assigned to receive carbetocin or a placebo, and d…
Early phase 1 • Sponsor: Alex Ekwueme Federal University Teaching Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New cancer pill enters first human tests
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…
Phase 1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental drug TJ037130 takes aim at advanced solid tumors
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…
Phase 1 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Oral drug elraglusib aims to tame advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…
Phase 1/2 • Sponsor: Actuate Therapeutics Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental shot aims to clear Hard-to-Treat HPV strains
Disease control Not yet recruitingThis study tests an experimental injection called BBM-C101 in 200 people with persistent HPV16 or HPV18 infection and low-grade precancerous lesions of the cervix, vulva, vagina, or anus. Participants receive four shots under the skin over three weeks. The trial monitors safety a…
Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
Disease control Not yet recruitingThis trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental shot aims to reverse HPV-Linked cervical precancer
Disease control Not yet recruitingThis study tests an experimental biologic, NWRD09, in women aged 18 to 65 with HPV16-positive cervical high-grade squamous intraepithelial lesions (HSIL), a precancerous condition. Participants receive four intramuscular injections over 12 weeks. The main goal is to see if the tr…
Phase 2 • Sponsor: Newish Biotech (Wuxi) Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New care model aims to close cancer treatment gaps for people with mental illness
Disease control Not yet recruitingThis trial tests a 24-week virtual care program called BRIDGE NET for people with serious mental illness who are starting cancer treatment. The program brings together oncology and mental health teams to plan care, provide early psychiatric support, and regularly check in with pa…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug aims to outsmart Chemotherapy-Resistant ovarian cancer
Disease control Not yet recruitingThis phase 3 trial tests an experimental drug called SYS6043 against standard chemotherapy in people with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants are randomly assigned to receive either SYS6043 or one of three standard chemotherapies…
Phase 3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental vaccine aims to clear precancerous cervical lesions without surgery
Disease control Not yet recruitingThis trial tests an experimental vaccine called SYS6026 in people with high-grade cervical lesions caused by HPV type 16 or 18. The goal is to see if the vaccine can help the body clear the virus and reverse the lesions, potentially avoiding the need for surgery. Participants are…
Phase 2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Can a daily supplement help the body fight off HPV?
Disease control Not yet recruitingThis study tests whether a daily oral supplement containing green tea extract (EGCG), folic acid, vitamin B12, and hyaluronic acid can help women clear a persistent human papillomavirus (HPV) infection. HPV is a common virus that can cause cervical cancer if it stays in the body …
Sponsor: IRCCS San Raffaele • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug XYA02 takes on tough cancers in first human trial
Disease control Not yet recruitingThis study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…
Phase 1/2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase 1/2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…
Phase 1/2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase 1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New PARP1 inhibitor targets Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …
Phase 1 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a Light-Activated cream replace surgery for cervical precancer?
Disease control Not yet recruitingThis study tests a new approach for treating high-grade cervical precancer (HSIL) using a cream called HAL that is activated by a special light, instead of standard surgery. About 230 women will be randomly assigned to receive either the light therapy or surgery. The main goal is…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for ovarian cancer: targeted drug combo takes on resistant tumors
Disease control Not yet recruitingThis phase II trial compares a new two-drug combination (sacituzumab govitecan plus bevacizumab) against standard chemotherapy (carboplatin, liposomal doxorubicin, and bevacizumab) in 87 women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor mainten…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Real-World check: targeted drug MIRV tested against tough ovarian cancer
Disease control Not yet recruitingThis study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug TAX2 targets Hard-to-Treat cancers in first human trial
Disease control Not yet recruitingThis study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…
Phase 1/2 • Sponsor: Apmonia Therapeutics • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo targets HPV-Driven cancers in phase II trial
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—SYS6026 and Enlonstobart—in people with advanced solid tumors that have spread and are linked to HPV types 16 or 18. The study aims to see if the combination is safe and shows signs of shrinking tumors. Participants must be at …
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Mesh-Like suture could cut hernia risk after cancer surgery
Disease control Not yet recruitingThis trial tests whether a special mesh-like suture (Duramesh) can prevent incisional hernias better than a standard slowly-absorbable suture (PDS loop) in women having abdominal surgery for gynecological cancers. About 300 participants will be randomly assigned to one of the two…
Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered herpes virus takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…
Phase 1/2 • Sponsor: Virogin Biotech Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase 2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Two-Drug combo aims to shrink vulvar tumors before surgery
Disease control Not yet recruitingThis trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Radiotherapy revolution: could 5 sessions replace 25 for endometrial cancer?
Disease control Not yet recruitingThis trial explores whether a new type of radiotherapy called CT online-adaptive radiotherapy can safely deliver treatment for endometrial cancer in just 5 sessions over a week and a half, instead of the usual 25 sessions over 5 weeks. The study includes 30 adults who have had su…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers
Disease control Not yet recruitingThis trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…
Phase 1 • Sponsor: Shanghai Gynecologic Oncology Group • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Targeted drug shows promise for rare vulvar cancer
Disease control Not yet recruitingThis phase 2 trial tests a drug called tisotumab vedotin in people with advanced squamous cell carcinoma of the vulva that has returned or spread. The drug is an antibody-drug conjugate designed to seek out and destroy cancer cells. The study aims to see how many participants' tu…
Phase 2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New hope for Platinum-Resistant ovarian cancer: BL-M07D1 enters phase 3 trial
Disease control Not yet recruitingThis Phase 3 trial compares a new drug called BL-M07D1 against standard chemotherapy in 404 people with HER2-expressing ovarian, fallopian tube, or peritoneal cancer that has become resistant to platinum-based treatment. Participants will receive either BL-M07D1 or one of several…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer
Disease control Not yet recruitingThis phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…
Phase 2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New shot aims to reverse cervical precancer without surgery
Disease control Not yet recruitingThis early-stage trial tests an injection called BBM-C101 in 60 women with high-grade cervical precancer linked to HPV16 or HPV18. The goal is to see if the drug is safe and can shrink or eliminate abnormal cells, potentially offering a non-surgical alternative. Participants rece…
Phase 1/2 • Sponsor: Shanghai Mianyi Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to make ovarian tumors operable
Disease control Not yet recruitingThis study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, the…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill shows promise for Hard-to-Treat ovarian cancer
Disease control Not yet recruitingThis study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers wi…
Phase 2 • Sponsor: Danatlas Pharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on Hard-to-Treat ovarian and endometrial cancers
Disease control Not yet recruitingThis early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…
Phase 1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Early phase 1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase 1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…
Early phase 1 • Sponsor: Base Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Two-Drug combo outsmart advanced cervical cancer?
Disease control Not yet recruitingThis study looks at how well a combination of two drugs, iparomlimab and tuvonralimab (called QL1706), works for people with recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. Researchers will compare outcomes of those receiving QL1706 to…
Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to tame advanced uterine cancer
Disease control Not yet recruitingThis study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initiall…
Phase 4 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
Disease control Not yet recruitingThis trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…
Phase 2 • Sponsor: Shandong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost cervical cancer survival
Disease control Not yet recruitingThis Phase II trial tests whether adding the immunotherapy drug cadonilimab to chemotherapy before surgery helps people with locally advanced cervical cancer live longer without the disease coming back. About 134 participants will be randomly assigned to receive either the drug c…
Phase 2 • Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase 1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can weight-loss drugs and hormones make endometrial cancer surgery safer for obese women?
Disease control Not yet recruitingThis study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…
Phase 4 • Sponsor: Hospital Universitari de Bellvitge • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase 1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New cocktail of drugs and vaccines takes on advanced ovarian cancer
Disease control Not yet recruitingThis phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal …
Phase 2 • Sponsor: Kalinski, Pawel, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Hormone blocker plus targeted drug shows promise against tough uterine cancer
Disease control Not yet recruitingThis phase II trial tests whether combining elacestrant, a drug that lowers estrogen, with everolimus, which stops cancer cells from growing and cuts their blood supply, can control advanced or recurrent ER+ endometrial cancer. About 50 adults whose cancer has returned or spread …
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
Disease control Not yet recruitingThis study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…
Phase 2 • Sponsor: GV20 Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for advanced HER2 cancers? drug trial launches
Disease control Not yet recruitingThis early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase 2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Drug attack aims to shrink cervical cancer tumors
Disease control Not yet recruitingThis Phase 2 trial tests a combination of three drugs—camrelizumab, famitinib, and standard chemotherapy—in 54 women with recurrent or metastatic cervical cancer that cannot be treated with surgery or radiation. The goal is to see if the combo shrinks tumors and controls the dise…
Phase 2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase 1/2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase 1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy-Chemo cocktail shows promise for shrinking cervical tumors before surgery
Disease control Not yet recruitingThis phase II trial is testing whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can help shrink tumors in women with early-stage cervical cancer (stages IB1-IB3). About 50 participants will receive the combination, then undergo conservative su…
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase 1/2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …
Early phase 1 • Sponsor: Peking University Shenzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase 1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immunotherapy duo aims to boost cervical cancer treatment before chemoradiation
Disease control Not yet recruitingThis study tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to chemotherapy before standard chemoradiation can help people with locally advanced cervical cancer live longer without the disease getting worse. About 486 adults aged 18-75 with stage III-IV…
Phase 3 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection targets cancer fluid in lungs and belly
Disease control Not yet recruitingThis early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…
Phase 1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase 1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Could a diabetes shot help beat uterine cancer without surgery?
Disease control Not yet recruitingThis study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase 1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug IN10028 tested for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…
Phase 1 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough ovarian cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug 'Unmasks' cancer cells to immune system in early trial
Disease control Not yet recruitingThis early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase 1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug senaparib tested in Real-World ovarian cancer study
Disease control Not yet recruitingThis study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …
Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase 4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SYS6051 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.
Phase 1 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Fibroid removal before IVF: a Game-Changer for fertility?
Disease control Not yet recruitingThis study looks at whether surgically removing uterine fibroids (myomectomy) before in vitro fertilization (IVF) helps women with infertility have a baby. About 792 women aged 20-39 with fibroids 4-6 cm that do not distort the uterine cavity will be randomly assigned to either h…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug FXB0871 takes on advanced cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can ancient herbs and modern therapy help ovarian cancer patients sleep better and live longer?
Disease control Not yet recruitingThis study tests whether a traditional Chinese herbal formula (Tiaoshen Anti-cancer granules) combined with cognitive behavioral therapy for insomnia (CBT-I) can improve sleep and possibly extend survival in 360 women with advanced ovarian cancer. Participants will receive either…
Phase 2/3 • Sponsor: Shanghai Municipal Hospital of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Not yet recruitingThis early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors.…
Phase 1 • Sponsor: Kumquat Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo targets advanced cervical cancer
Disease control Not yet recruitingThis study tests two experimental drugs, MRG003 and QL1706, together in people with cervical cancer that has returned or spread and no longer responds to standard chemotherapy. About 41 adults will receive the combination to see if it shrinks tumors. The goal is to control the di…
Phase 1/2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Snake venom protein tested as cancer treatment in humans
Disease control Not yet recruitingThis early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…
Phase 1 • Sponsor: Celtic Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo for BRCA ovarian cancer enters early testing
Disease control Not yet recruitingThis early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…
Phase 1 • Sponsor: Chong Kun Dang Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase 1/2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill shows promise for Hard-to-Treat uterine cancer
Disease control Not yet recruitingThis phase 2 trial is testing a daily pill called Inavolisib in about 48 people with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug targets that mutation to try to shrink tumors or stop them from growing. Researchers will measure how ma…
Phase 2 • Sponsor: National Cancer Institute, Naples • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase 1/2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Shorter radiation with Real-Time adjustments could reduce side effects
Disease control Not yet recruitingThis study tests whether daily adaptive radiotherapy (ART) can safely deliver shorter, more intense radiation treatments for prostate, endometrial, cervical, and rectal cancers. About 264 participants will be randomly assigned to standard radiation or ART, which uses daily imagin…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
MRI-guided radiation aims to slash side effects in endometrial cancer
Disease control Not yet recruitingThis study tests a new way to deliver radiotherapy for endometrial cancer after surgery. Using real-time MRI guidance, doctors can target radiation more accurately and reduce damage to nearby organs like the bowel and bladder. About 61 women will receive five high-dose sessions o…
Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Minimally invasive surgery may offer safer option for early endometrial cancer
Disease control Not yet recruitingThis study compares two surgical approaches for early-stage endometrial cancer: laparoscopic staging (minimally invasive) and open staging laparotomy (traditional open surgery). Researchers will enroll 30 patients to see if laparoscopy is as safe and effective as open surgery, wi…
Sponsor: Ain Shams Maternity Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …
Phase 1/2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for advanced cervical cancer: experimental drug combo enters trial
Disease control Not yet recruitingThis study tests whether adding the experimental drug JSKN033 to standard chemotherapy (with or without bevacizumab) is safe and effective for people with advanced cervical cancer that has spread or come back. About 78 adults will take part. The goal is to control the disease and…
Phase 2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New triple therapy aims to stall return of ovarian cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Vulvar cancer study aims to spare women from unnecessary surgery
Disease control Not yet recruitingThis study tests whether regular ultrasound checks of the groin can safely replace the standard surgery to remove lymph nodes in women with early-stage vulvar cancer. The goal is to reduce side effects and improve recovery while still keeping the cancer under control. About 640 w…
Phase 3 • Sponsor: Queensland Centre for Gynaecological Cancer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug SIG001 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…
Phase 1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New vaccine combo aims to outsmart ovarian cancer resistance
Disease control Not yet recruitingThis phase 2 trial tests whether a peptide vaccine (NY-ESO-1) combined with an immunotherapy drug (toripalimab-tpzi) can prevent resistance to treatment in 24 women with stage III/IV ovarian cancer that no longer responds to platinum chemotherapy. The vaccine primes the immune sy…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New vaccine targets tough ovarian cancer in tiny trial
Disease control Not yet recruitingThis early study tests a personalized vaccine (YS247) made from a patient's own immune cells to fight a specific type of ovarian cancer (HRD-negative). Only 9 women who haven't been cured by standard therapy will take part. The main goal is to check safety, not yet to prove it wo…
Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug cocktail aims to stop cervical cancer comeback after surgery
Disease control Not yet recruitingThis study tests whether a combination of two drugs (camrelizumab and famitinib) can help prevent cervical cancer from returning after surgery. It involves 30 women with specific cancer types and PD-L1 positive tumors. The main goal is to see how many patients remain cancer-free …
Sponsor: Jin LI • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug WSK-IM02 takes on Hard-to-Treat ovarian cancer
Disease control Not yet recruitingThis early-phase trial is testing an experimental drug called WSK-IM02 in 36 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard platinum chemotherapy. The drug is given as an injection into the abdomen. The main goal is to check saf…
Phase 1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Sound waves vs. watchful waiting: can HIFU clear cervical lesions faster?
Disease control Not yet recruitingThis study compares a non-invasive ultrasound treatment (HIFU) to standard observation for low-grade cervical lesions (LSIL/CIN1) in 180 pre-menopausal women. Most of these lesions go away on their own, but the trial aims to see if HIFU can speed up clearance of the lesion and th…
Sponsor: Queen Mary Hospital, Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug QLS5308 enters human testing for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…
Phase 1/2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control Not yet recruitingThis study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if t…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for cervical cancer patients who Can't take chemo
Disease control Not yet recruitingThis phase II trial tests a drug called cadonilimab combined with radiation therapy for women with advanced cervical cancer who cannot receive standard chemotherapy due to age or health issues. The study will enroll 45 participants and measure how many have a complete response (n…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New pill plus immunotherapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growt…
Phase 2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
3D-Printed device could improve radiation for cervical cancer
Disease control Not yet recruitingThis study tests a new, custom-made 3D-printed applicator for delivering high-dose radiation (brachytherapy) to treat locally advanced cervical cancer. About 25 participants will receive the treatment to see if the device works safely and as planned. The goal is to improve how ra…
Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy aims to shrink ovarian tumors before surgery
Disease control Not yet recruitingThis study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal …
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug T320 targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase 1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a simpler surgery be safer for aggressive uterine cancer?
Disease control Not yet recruitingThis study compares two surgical approaches for women with early-stage, high-risk endometrial cancer that has a p53 gene mutation. One group will get the standard extensive lymph node removal, while the other gets a less invasive sentinel node biopsy. The goal is to see if the si…
Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called KT032 in 24 adults with advanced solid tumors (ovarian, mesothelioma, colon cancer) that have spread to the abdomen and haven't responded to standard treatments. The main goal is to check safety and find the best dose, while …
Early phase 1 • Sponsor: Weijia Fang, MD • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill may help cancer patients avoid chemo delays due to low platelets
Disease control Not yet recruitingThis study tests a daily pill called hetrombopag to see if it can safely raise low platelet counts in women with gynecological cancers (like ovarian or cervical cancer) after chemotherapy. About 244 women whose platelets dropped too low will take the drug to help them complete th…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Engineered macrophages take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…
Early phase 1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
One shot to stop HPV spread? new trial tests Vaccine's hidden power
Disease control Not yet recruitingThis phase 2 trial tests whether a single dose of the HPV vaccine (Gardasil-9) can reduce the infectivity of high-risk HPV in women aged 18-29 who already have the virus. Researchers will compare cervical samples from vaccinated and unvaccinated women at 6 months to see if vaccin…
Phase 2 • Sponsor: Institut d'Investigació Biomèdica de Bellvitge • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail aims to shrink ovarian tumors before surgery
Disease control Not yet recruitingThis Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enou…
Phase 2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a single chemo drug replace the standard doublet for some ovarian cancers?
Disease control Not yet recruitingThis study compares a single chemotherapy drug (paclitaxel) to the standard two-drug combo (paclitaxel plus carboplatin) as initial treatment before surgery for advanced ovarian cancer. It is for patients whose tumors have high levels of a protein called PARK2, which may make the…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Ovarian cancer trial uses KELIM score to personalize surgery timing
Disease control Not yet recruitingThis study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more c…
Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for advanced cervical cancer: drug combo trial launches
Disease control Not yet recruitingThis Phase 3 trial tests whether a combination of two drugs, WX390 and toripalimab, can help people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemotherapy. About 440 participants will be randomly assigned to receive either the new combi…
Phase 3 • Sponsor: Shanghai Jiatan Pharmatech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug duo aims to extend remission in advanced ovarian cancer
Disease control Not yet recruitingThis study tests whether a combination of two drugs (fluzoparib and famitinib) can help keep advanced ovarian cancer from returning after successful initial chemotherapy. About 43 women with stage III-IV ovarian cancer who responded to platinum-based chemo will take these pills d…
Phase 2 • Sponsor: Jinhua Zhou • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a drug combo replace the knife for some endometrial cancers?
Disease control Not yet recruitingThis study tests two immunotherapy drugs (iparomlimab and tuvonralimab) in 30 women with a specific type of endometrial cancer that is mismatch repair-deficient. The goal is to see if the treatment can make the cancer disappear or shrink enough to avoid surgery. Participants must…
Phase 2 • Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for ovarian cancer: drug combo targets relapsed patients
Disease control Not yet recruitingThis Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…
Phase 2 • Sponsor: Onconic Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail aims to stop cervical cancer return
Disease control Not yet recruitingThis phase II trial tests whether adding pembrolizumab and lenvatinib to standard chemoradiation and brachytherapy can improve outcomes for adults with high-risk locally advanced cervical cancer. About 87 participants will receive the drug combination and be followed for two year…
Phase 2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Promising drug cocktail targets Hard-to-Treat cervical cancer
Disease control Not yet recruitingThis phase II trial tests a combination of two drugs—Utidelone and Toripalimab—in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkage …
Phase 2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to shrink ovarian tumors in Hard-to-Treat patients
Disease control Not yet recruitingThis phase 2 trial tests two oral drugs, zeprumetostat and fuzuloparib, in 30 people with advanced or recurrent ovarian cancer who do not have BRCA gene mutations. The goal is to see if the combination can shrink tumors and delay progression. Participants first take fuzuloparib a…
Phase 2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Microtransplantation: a new hope for advanced cancer patients?
Disease control Not yet recruitingThis early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …
Phase 1 • Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug combo aims to shrink Hard-to-Operate ovarian tumors
Disease control Not yet recruitingThis study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …
Phase 2 • Sponsor: Qinglei Gao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Supercharged T-Cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …
Early phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug cocktail aims to shrink cervical tumors before surgery
Disease control Not yet recruitingThis study tests a combination of three drugs (sacituzumab tirumotecan, iparomlimab, and tuvonralimab) given before surgery to people with locally advanced cervical cancer. The goal is to see if the treatment can completely eliminate the tumor before the operation. About 25 parti…
Phase 2 • Sponsor: Zheng Min • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …
Phase 1/2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase 1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug HX111 enters early human trials
Disease control Not yet recruitingThis study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase 1/2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to fix Chemo-Caused low platelets
Disease control Not yet recruitingThis Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Phase 1/2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo shows promise in early trial
Disease control Not yet recruitingThis study tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) in 30 women with platinum-resistant recurrent ovarian cancer, a type that is very hard to treat. The goal is to see if the combo can shrink tumors better than current options. Participants must …
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New targeted drug shows promise for Hard-to-Treat gynecologic cancers
Disease control Not yet recruitingThis study tests a new drug called BRY812 in people with advanced ovarian, endometrial, or ovarian clear cell cancers that have a specific marker (LIV-1). The goal is to see if the drug can shrink tumors and how safe it is. About 56 participants will receive the drug, and researc…
Phase 2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…
Phase 2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for rare cancers: china launches massive drug trial
Disease control Not yet recruitingThis study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…
Phase 1/2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Light therapy shows promise against HPV-Linked cervical precancer
Disease control Not yet recruitingThis study tests a treatment called photodynamic therapy (PDT) for women with low-grade cervical precancer caused by HPV types 16 or 18. A photosensitizing cream is applied to the cervix, then activated with light to destroy abnormal cells. The trial will compare 225 women who re…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Light therapy could replace surgery for cervical precancer
Disease control Not yet recruitingThis study compares a light-activated gel treatment (ALA-PDT) to standard surgery (LEEP) for women with high-grade cervical precancer (HSIL/CIN2). About 560 women will receive either the gel plus red light therapy or surgery. The goal is to see if the gel treatment works as well …
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase 1/2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can surgery buy more time for ovarian cancer patients?
Disease control Not yet recruitingThis study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The …
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New gene therapy trial hopes to tame advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail aims to fight advanced uterine cancer
Disease control Not yet recruitingThis Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive eithe…
Phase 3 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for advanced endometrial cancer: Triple-Drug combo enters safety testing
Disease control Not yet recruitingThis phase 2 trial tests whether adding a repurposed drug called EG-007 to the standard combination of lenvatinib and pembrolizumab is safe for people with advanced or recurrent endometrial cancer. The study will enroll 28 adults whose cancer has progressed after platinum chemoth…
Phase 2 • Sponsor: Evergreen Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New drug combo shows promise for tough cervical cancers
Disease control Not yet recruitingThis study will observe 1,300 patients with advanced or recurrent cervical cancer who are treated with camrelizumab, famitinib, or combinations of these drugs. The goal is to see how safe and effective these treatments are in real-world settings. Patients are placed into one of s…
Sponsor: Qi Zhou • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New surgical technique aims to reduce cancer spread in cervical cancer patients
Disease control Not yet recruitingThis study compares two surgical methods for early-stage cervical cancer (IB2-IIA1). One is traditional open surgery, and the other is a minimally invasive approach using a stapler to prevent cancer cells from spreading. About 494 participants will be followed for 4.5 years to se…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase 1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could less radiation be better for cervical cancer?
Disease control Not yet recruitingThis study tests whether shrinking the radiation target area after chemotherapy can safely control stage IIb cervical cancer. Sixty participants will receive induction chemo followed by radiation that covers only the uterus, nearby tissues, and a small margin below the tumor. The…
Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New heat therapy could free women from fibroid surgery
Disease control Not yet recruitingThis study tests a minimally invasive treatment called microwave ablation for uterine fibroids. It uses heat to shrink fibroids and reduce symptoms like heavy bleeding and pelvic pressure, while preserving the uterus. The study will enroll 20 premenopausal women with fewer than f…
Sponsor: Jihad Hussien Mohamed Mahmoud • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
One-Time radiation procedure could transform cervical cancer care
Disease control Not yet recruitingThis study looks at whether a single, image-guided radiation implant can control advanced cervical cancer as well as the usual multiple implants. About 400 women from six French hospitals who had this single-implant treatment between 2014 and 2024 will have their medical records …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase 1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase 1/2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New targeted cancer therapy begins first human testing
Disease control Not yet recruitingThis is the first human study of an experimental cancer drug called M7437, which targets a specific protein found on certain tumor cells. The study will test the safety, side effects, and early effectiveness of M7437 in 138 people with advanced solid tumors that have stopped resp…
Phase 1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Jan 26, 2026 13:59 UTC
-
New PET tracer aims to light up hidden cancer targets
Diagnosis Not yet recruitingResearchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…
Early phase 1 • Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Mapping the DNA test that decides who gets PARP inhibitors
Diagnosis Not yet recruitingResearchers are reviewing medical records from about 1,125 women in Italy with newly diagnosed advanced high-grade epithelial ovarian cancer. The study focuses on how hospitals test tumors for homologous recombination deficiency (HRD), a DNA repair flaw that can make PARP inhibit…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive antibody aims to light up hidden solid tumors
Diagnosis Not yet recruitingResearchers are testing a new imaging agent called 111In-TJD-31 that targets placental alkaline phosphatase (ALPP), a protein found on many solid tumor cells but rarely in healthy adult tissue. The study enrolls 8 participants: 2 healthy volunteers who give blood samples and 6 pa…
Phase 1 • Sponsor: Yong He • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
AI reads tumor slides to match cancer patients with trials
Diagnosis Not yet recruitingMany cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can a simple blood test spot ovarian cancer before it starts?
Diagnosis Not yet recruitingThis study is looking at whether a blood test called Galleri can help detect ovarian cancer early in people with BRCA1 or BRCA2 gene changes, who are at higher risk. Participants will give a blood sample and answer questionnaires about their experience. The study will also check …
Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
AI reads ultrasound images to spot ovarian cancer risk
Diagnosis Not yet recruitingThis study tests whether machine learning can analyze ultrasound images to distinguish benign from malignant adnexal masses, growths near the ovaries that are common but hard to classify. Researchers will develop and validate AI models using images from 12,000 patients across mul…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
Can a new tracer reveal hidden tumors?
Diagnosis Not yet recruitingThis trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …
Early phase 1 • Sponsor: Lumina Pharmaceuticals Inc • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
Can a new imaging tracer light up ovarian cancer cells?
Diagnosis Not yet recruitingThis trial tests a new PET/CT tracer called 89Zr-DFO-Mirvetuximab, which targets a protein (FRα) found on many ovarian cancer cells. Researchers will give the tracer to 20 people with advanced or recurrent ovarian cancer and take scans at several time points. They will compare th…
Early phase 1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 29, 2026 00:00 UTC
-
A simple breath test might spot multiple cancers before symptoms appear
Diagnosis Not yet recruitingThis trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a new imaging tracer outperform standard scans in finding hidden tumors?
Diagnosis Not yet recruitingThis trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New imaging tool could help surgeons detect hidden cancer cells during surgery
Diagnosis Not yet recruitingThis study tests a new imaging technique that could help surgeons see if cancer has spread to lymph nodes during surgery for gynecologic cancers like ovarian, endometrial, cervical, and vulvar cancer. The method uses a special microscope to examine lymph node tissue right after i…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New blood tests aim to catch ovarian cancer earlier
Diagnosis Not yet recruitingThis study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the b…
Sponsor: National and Kapodistrian University of Athens • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Blood test may spot ovarian cancer return months before scans
Diagnosis Not yet recruitingThis study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to s…
Sponsor: Asan Medical Center • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New blood test could spot cervical cancer early in High-Risk women
Diagnosis Not yet recruitingThis study aims to develop a blood test that can accurately detect serious cervical lesions in women infected with HPV16 or HPV18, the high-risk types linked to cervical cancer. Researchers will collect blood samples and medical data from about 1,465 women across three hospitals …
Sponsor: Women's Hospital School Of Medicine Zhejiang University • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
New blood test aims to catch ovarian cancer sooner
Diagnosis Not yet recruitingThis study will test a new blood test that looks for DNA changes to detect ovarian cancer, especially in early stages. Researchers will compare test results from 1,000 women with and without ovarian cancer to see how accurate it is. If it works well, it could lead to a simple scr…
Sponsor: Tongji Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New Self-Sampling and digital colposcopy could speed up cervical cancer detection
Diagnosis Not yet recruitingThe PRIORITY study is testing a new approach to diagnose cervical cancer earlier by combining self-sampling at home with digital colposcopy and telemedicine. Researchers will enroll 700 women aged 30 to 65 to see if this method is more accurate and faster than current care. The g…
Sponsor: Pontificia Universidad Catolica de Chile • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
New 'Smart' PET scan could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Could a simple scan replace biopsies for cancer immunotherapy?
Diagnosis Not yet recruitingThis study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Could a Tampon-Like device catch hidden cancers early?
Diagnosis Not yet recruitingThis study is testing a new medical device that gently collects cells from the vagina to look for signs of ovarian and endometrial cancers. The goal is to see if this less invasive method can accurately detect these cancers compared to standard tests. About 300 women, some with c…
Sponsor: Ellele Health • Aim: Diagnosis
Last updated Jun 27, 2026 09:07 UTC
-
Pap smear upgrade? DNA test could spot hidden uterine cancer
Diagnosis Not yet recruitingThis observational study will test a new molecular test called CISENDO, which looks at DNA methylation in cells from a routine cervical smear. The goal is to see if it can accurately detect endometrial cancer or precancerous lesions in women at medium-to-high risk. Researchers wi…
Sponsor: Peking Union Medical College Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New needle biopsy could spare women unnecessary uterus surgery
Diagnosis Not yet recruitingThis study tests a new, less invasive biopsy method for uterine masses. The procedure uses a thin needle guided by ultrasound through the cervix to take a tissue sample. Researchers want to see if it can accurately tell benign from malignant growths, potentially helping women avo…
Sponsor: Assiut University • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
AI reads laparoscopy videos to guide ovarian cancer surgery
Diagnosis Not yet recruitingThis study tests whether artificial intelligence (AI) can predict the type of ovarian cancer and how well surgery might work by analyzing videos from a diagnostic laparoscopy. Researchers will collect videos from 100 women with advanced ovarian cancer and train an AI to recognize…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
New DNA sequencer could make genetic testing cheaper and faster
Diagnosis Not yet recruitingThis study compares a new DNA sequencing platform (MGI) against the current standard (Illumina) for diagnosing hereditary cancers like breast and ovarian cancer, Lynch syndrome, and intestinal polyposis. Researchers will analyze 248 patient samples using both platforms to see if …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 26, 2026 14:56 UTC
-
Double probe heat therapy may slash cervical cancer risk in HIV-positive women
Prevention Not yet recruitingThis study will test if using two heat probes instead of one can better prevent cervical cancer in 300 women with HIV in Zimbabwe. The standard single-probe treatment often fails in these women. The goal is to see if the two-probe method is safe, acceptable, and more effective at…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
A digital coach may guide patients through cervical cancer prevention
Prevention Not yet recruitingThis trial tests whether an animated health coach on a smartphone can help people who have abnormal cervical cancer screening results get the follow-up care they need. Many people skip these appointments, which can lead to preventable cancer. The study will enroll 750 adults aged…
Sponsor: Tufts Medical Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
New probe technique could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingThis study tests whether using two probes during a heat-based treatment (thermal ablation) works better than the usual one-probe method to prevent cervical cancer in women living with HIV. About 200 women aged 25-49 with HIV and cervical precancer will be enrolled. The goal is to…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Two probes better than one? new study aims to cut cervical cancer in women with HIV
Prevention Not yet recruitingThis study will test whether using two heat probes instead of one to treat cervical precancer works better for women living with HIV. Researchers in Rwanda will enroll 300 women to see if the two-probe approach is safe, acceptable, and more effective at clearing HPV. The goal is …
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
Double probe heat therapy could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingThis study tests whether using two heat probes instead of one can better prevent cervical cancer in women living with HIV, who face a much higher risk. Researchers will enroll 300 women in Kenya to see if the two-probe method is safe, acceptable, and more effective at clearing HP…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 06, 2026 00:00 UTC
-
A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
Prevention Not yet recruitingThis study tests whether it is practical and safe to remove the fallopian tubes during planned weight-loss (bariatric) surgery as a way to lower the risk of ovarian cancer. Many ovarian cancers are thought to start in the fallopian tubes, and removing them can reduce risk by abou…
Early phase 1 • Sponsor: St. Joseph's Healthcare Hamilton • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC
-
Zimbabwe study targets cancer prevention with vaccines and mental health care
Prevention Not yet recruitingThis study in Zimbabwe will screen women of childbearing age and high school students for HPV and Hepatitis B, then offer vaccines to those who are eligible. It also includes cognitive behavioral therapy for mental health issues. The goal is to see if this combined approach can p…
Phase 4 • Sponsor: Eunice Dube • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
New trial aims to slash deadly bloodstream infections from hospital tubes
Prevention Not yet recruitingThis study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…
Sponsor: The University of Queensland • Aim: Prevention
Last updated Jul 19, 2026 00:00 UTC
-
Acupuncture needles aim to stop Chemo's nerve pain
Prevention Not yet recruitingThis study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …
Sponsor: Affiliated Hospital of Qinghai University • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Acupuncture with a jolt: could needles shield nerves from chemo?
Prevention Not yet recruitingThis study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…
Sponsor: Affiliated Hospital of Qinghai University • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Ovarian cancer prevention: a simple Add-On during gallbladder surgery?
Prevention Not yet recruitingThis study tests whether removing the fallopian tubes at the same time as gallbladder surgery is safe and practical. Ovarian cancer often starts in the fallopian tubes, so removing them may prevent it. The trial will enroll 240 women aged 35 and older to see if the extra procedur…
Sponsor: University of British Columbia • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Mobile health unit brings cervical cancer screening to the unhoused
Prevention Not yet recruitingThis study aims to make cervical cancer screening easier for people who are unhoused or unstably housed. Researchers will bring a mobile health unit to community locations in Tucson, Arizona, where participants can learn about cervical cancer, collect their own sample for HPV tes…
Sponsor: University of Arizona • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC
-
Simple HPV test before hysterectomy could stop cervical cancer before it starts
Prevention Not yet recruitingThis study checks if testing for high-risk HPV before a subtotal hysterectomy can help prevent cervical cancer. About 300 women scheduled for this surgery will get an HPV test; if positive, they will have a cone biopsy to remove any precancerous cells during the same operation. T…
Sponsor: General University Hospital, Prague • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Can a broader HPV vaccine boost protection after the original shot?
Prevention Not yet recruitingThis study will test if giving a 9-valent HPV vaccine to women who previously received the bivalent HPV vaccine is safe and boosts their immune response. Researchers will enroll 360 healthy women aged 18-45 and compare two different dosing schedules (two doses vs. three doses) ag…
Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Can a simple cream shield cancer patients from radiation burns?
Prevention Not yet recruitingThis study tests whether a cream called triethanolamine (Trolamine) can prevent or reduce vaginal inflammation caused by radiation therapy in cervical cancer patients. About 238 women will either use the cream daily during radiotherapy plus routine care, or receive routine care a…
Phase 4 • Sponsor: Fujian Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
One shot to prevent cancer: new HPV vaccine tested in zambia
Prevention Not yet recruitingThis study tests whether a single dose of the CERVAVAC HPV vaccine works as well as a single dose of Gardasil in preventing HPV infection. About 1,266 girls, boys, and young women in Zambia will receive one shot of either vaccine. Researchers will check their immune response at 6…
Phase 4 • Sponsor: International Agency for Research on Cancer • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
New Two-Step surgery could spare High-Risk women from early menopause
Prevention Not yet recruitingThis study tests a new two-step preventive surgery for women with gene mutations (like BRCA1) that raise their risk of ovarian cancer. Instead of removing both ovaries and fallopian tubes at once, the first step removes only the fimbria (the end of the fallopian tube), and the ov…
Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Jun 27, 2026 11:02 UTC
-
HPV vaccine may stop precancerous lesions from returning
Prevention Not yet recruitingThis study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive eith…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC
-
Kenya project aims to eradicate cervical cancer with HPV vaccine and better screening
Prevention Not yet recruitingThis study continues a community project in rural Kenya to prevent cervical cancer. It offers the 9-valent HPV vaccine to 2000 adolescent girls and tests self-collected swabs for high-risk HPV in adult women. Researchers will also study why some families do not participate and wh…
Sponsor: Indiana University • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC
-
Bone drug may shield cancer survivors from crippling fractures
Prevention Not yet recruitingThis study tests whether alendronate, a drug used for osteoporosis, can prevent pelvic fractures in cervical cancer patients who have had chemotherapy and radiation. About 65 adults with non-metastatic cervical cancer will receive alendronate to see if it strengthens bones and re…
Phase 1/2 • Sponsor: Dr. Itay GoorAryeh • Aim: Prevention
Last updated Jun 27, 2026 07:59 UTC
-
New program aims to boost cervical cancer screening rates across the U.S.
Prevention Not yet recruitingThis study tests a program that helps doctors improve cervical cancer screening and follow-up for patients who are overdue. The program combines education with quality improvement methods and allows clinicians to earn board certification credits. Researchers will enroll 80,000 pa…
Sponsor: Boston Medical Center • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
New gel aims to stop uterine scarring after surgery
Prevention Not yet recruitingThis study looks at whether a gel called Hyalosem can prevent scar tissue from forming inside the uterus after surgery. Researchers will review the medical records of 80 women who had uterine surgery and then received the gel. The goal is to see if the gel reduces adhesions and i…
Sponsor: Semikal Technology • Aim: Prevention
Last updated Jun 26, 2026 14:44 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could early palliative care reduce aggressive End-of-Life cancer treatments?
Symptom relief Not yet recruitingThis study looks at whether bringing in palliative care early during an unplanned hospital stay can reduce aggressive treatments at the end of life for people with advanced cancer. About 493 adults with metastatic digestive, gynecological, ENT, or sarcoma cancers will be randomly…
Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Can a Needle-Free device make vulvar biopsies less painful?
Symptom relief Not yet recruitingThis trial compares two ways of numbing the vulva before a biopsy: a needle-free device called the J-Tip and the standard lidocaine shot. About 106 adults scheduled for a vulvar biopsy will be randomly assigned to one of the two methods. Participants will rate their pain and nerv…
Sponsor: Tufts Medical Center • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
A lifeline for cancer caregivers: can simple phone support reduce their stress?
Symptom relief Not yet recruitingThis pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Robot companions may soothe cancer Patients' emotional turmoil
Symptom relief Not yet recruitingThis trial tests a supportive care program called E-MOTE, delivered by an AI-assisted robot during hospital stays and a mobile app after discharge, for women newly diagnosed with gynecologic cancer who are undergoing surgery. The program includes emotional assessments, empathetic…
Sponsor: National Taiwan University Hospital • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Could gentle yoga and breathing ease Cancer's lingering toll?
Symptom relief Not yet recruitingThis trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…
Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Telling your story may ease the double stigma of cancer and HIV — a trial puts it to the test
Symptom relief Not yet recruitingThis study tests whether watching storytelling videos and writing or talking about personal experiences can reduce stigma and improve quality of life for women living with both cervical cancer and HIV in Zambia. Participants are randomly assigned to different combinations of stor…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Can acupuncture help women regain bladder control after hysterectomy?
Symptom relief Not yet recruitingThis trial investigates whether acupuncture can help women who have trouble urinating after a radical hysterectomy for cervical cancer. Participants receive either real acupuncture or a sham version (using non-penetrating needles) alongside standard care with a catheter and medic…
Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could a common muscle relaxant cut narcotic use after hysterectomy?
Symptom relief Not yet recruitingThis study tests whether adding cyclobenzaprine, a muscle relaxant, to standard pain medicines (ibuprofen, acetaminophen, and short-term narcotics) improves pain control and reduces narcotic use after minimally invasive hysterectomy. About 36 women undergoing laparoscopic hystere…
Phase 4 • Sponsor: Christiana Care Health Services • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Vitamins e and CoQ10 tested as shield against radiation damage
Symptom relief Not yet recruitingThis study tests whether taking high doses of vitamin E and CoQ10 daily for 90 days can reduce chronic side effects from pelvic radiation in people treated for prostate, uterine, cervical, or anal cancer. Researchers will monitor safety, side effects, and quality of life in 200 a…
Phase 1/2 • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Ice chips vs. mouth sores: simple trick may ease chemo side effect
Symptom relief Not yet recruitingThis study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Prepping for surgery: could exercise and diet before the knife cut complications?
Symptom relief Not yet recruitingThis study looks at whether a prehabilitation program—including physical therapy, dietary advice, and emotional support—given before major cancer surgery can reduce deaths and serious complications within 30 days after the operation. About 180 adults with cancers of the pancreas,…
Sponsor: Fox Chase Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Hypnosis may ease chemo anxiety in teens and young adults
Symptom relief Not yet recruitingThis study tests whether a single hypnosis session during chemotherapy can reduce anxiety and other side effects like nausea in young people with cancer. It includes 70 participants aged 15-49 with sarcoma, germ cell tumors, or breast cancer. Researchers will compare anxiety leve…
Sponsor: Institut Bergonié • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can exercise and coaching before ovarian cancer surgery help? a new pilot trial aims to find out
Symptom relief Not yet recruitingThis pilot trial will test whether a prehabilitation program (exercise, protein drinks, breathing exercises, and coaching) is feasible for women awaiting ovarian cancer surgery. It compares in-person delivery, remote delivery via a web app, and standard education-only care. The s…
Sponsor: Jordan Leitch • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
Can Pre-Surgery training improve recovery in gynecologic cancer?
Symptom relief Not yet recruitingThis pilot study tests whether a physiatry-led prehabilitation program—including exercise, nutrition, and mind-body practices—can help women with advanced gynecologic cancer stay stronger before surgery. Twenty-five participants will follow the program during their neoadjuvant tr…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New surgical trick may cut bleeding in hysterectomy
Symptom relief Not yet recruitingThis study tests whether cauterizing the uterine artery at its origin before removing the uterus via laparoscopy reduces blood loss and surgery time compared to the standard technique. It will involve 44 women over 35 with non-cancerous conditions like fibroids or abnormal bleedi…
Sponsor: Kafrelsheikh University • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Simple exercises may soothe chemo nerve damage
Symptom relief Not yet recruitingThis study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…
Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New recovery protocol aims to get hysterectomy patients home sooner
Symptom relief Not yet recruitingThis study tests whether a special care plan called Enhanced Recovery After Surgery (ERAS) helps women recover faster after a hysterectomy. About 78 women will be randomly assigned to either ERAS or standard care. The goal is to see if ERAS shortens hospital stays and reduces pai…
Sponsor: Cairo University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Miracle fruit may bring back taste for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can a Plant-Based diet improve life for women with metastatic cancer?
Symptom relief Not yet recruitingThis study tests whether a whole food, plant-based diet combined with behavioral education can improve quality of life and diet adherence in 60 women with metastatic breast or endometrial cancer. Participants are randomly assigned to either the plant-based diet with support or a …
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New online tool aims to ease Cancer's toll on patients and loved ones
Symptom relief Not yet recruitingThis study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…
Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
New surgical bag may speed up fibroid removal
Symptom relief Not yet recruitingThis trial tests a new single-channel bag used during keyhole surgery to remove uterine fibroids. The bag holds the fibroid while it is cut into smaller pieces, and the goal is to see if it makes the surgery faster and simpler than the current two-channel bag. About 78 women aged…
Sponsor: First People's Hospital of Hangzhou • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Can starting prehab early boost ovarian cancer outcomes?
Symptom relief Not yet recruitingThis study compares two types of prehabilitation (exercise, nutrition, and psychological support) for 225 women with advanced ovarian cancer. One group starts prehab early during chemotherapy, while the other starts just before surgery. The goal is to see if early prehab reduces …
Sponsor: Hospital Clinic of Barcelona • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Could a tiny electrical zap ease pelvic pain after fibroid procedure?
Symptom relief Not yet recruitingThis study tests a device called TUNES, which delivers gentle electrical stimulation through a menstrual disc to nerves near the uterus. The goal is to see if it can reduce pain and the need for pain medication in 60 women after uterine fibroid embolization. Participants will be …
Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Exercise trial aims to reverse muscle loss in cancer survivors
Symptom relief Not yet recruitingThis study tests whether a supervised exercise program can help women who have had breast or gynecological cancer and now suffer from muscle loss (sarcopenia). The 78 participants will do resistance, aerobic, balance, and stretching exercises. Researchers will measure changes in …
Sponsor: State University of Londrina • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Mindfulness may boost hope and coping in gynecological cancer patients
Symptom relief Not yet recruitingThis study tests whether an 8-week online mindfulness program can improve hope, emotional coping, quality of life, and psychological well-being in women with gynecological cancer. About 96 women currently receiving treatment will be randomly assigned to either the mindfulness pro…
Sponsor: Ondokuz Mayıs University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New radiation technique aims to prevent dangerous blood drops in cervical cancer patients
Symptom relief Not yet recruitingThis study tests whether a new way of planning radiation—sparing the pelvic and lower spine bones—can lower the risk of severe blood-related side effects in women with advanced cervical cancer. About 72 participants will receive standard chemoradiotherapy, but half will have thei…
Sponsor: Institut Paoli-Calmettes • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New program aims to boost sexual health after cervical cancer
Symptom relief Not yet recruitingThis study will test a program that combines sexual health support and lifestyle changes for women treated for cervical cancer. The goal is to see if it improves their sexual function and quality of life compared to standard care. 120 women from hospitals in Spain will take part.
Phase 4 • Sponsor: Fundacion Clinic per a la Recerca Biomédica • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Personalized diet may boost Well-Being in advanced cancer patients
Symptom relief Not yet recruitingThis study tests whether a personalized diet can improve quality of life in 100 women with advanced gynecologic or breast cancer who are receiving antibody-drug conjugate therapy. Participants will either follow a diet tailored to their needs or receive general Mediterranean diet…
Phase 2 • Sponsor: TNC Nutrición Terapéutica S.L. • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Exercise may ease Chemo's nerve pain, new study hopes to prove
Symptom relief Not yet recruitingThis study looks at whether exercise can lessen nerve damage caused by certain chemotherapy drugs. About 140 people with colorectal or gynecologic cancer will either exercise or receive usual care. Researchers will measure nerve function, blood markers, and quality of life to see…
Sponsor: National Cancer Center, Korea • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Chlorophyll-Based supplement may ease radiation damage in cervical cancer patients
Symptom relief Not yet recruitingThis phase 3 trial tests whether a daily dose of sodium-copper-chlorophyllin, a chlorophyll derivative, can reduce long-term bladder and bowel side effects from radiation therapy in 316 women with locally advanced cervical cancer. Participants take the supplement for 3 months aft…
Phase 3 • Sponsor: Tata Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Herbal soak may soothe Chemo's painful side effects
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…
Sponsor: Peking University Third Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New therapy aims to ease trauma in ovarian cancer patients
Symptom relief Not yet recruitingThis phase III trial tests a therapy called CALM-TF for women with advanced ovarian cancer who experience traumatic stress. 300 participants will either receive 3-6 sessions of this trauma-focused therapy or standard care. Researchers will measure stress, depression, and quality …
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Simple hand and foot moves may ease chemo nerve pain in older cancer patients
Symptom relief Not yet recruitingThis study looks at whether hand and foot exercises can reduce nerve pain (numbness, tingling) and improve quality of life in adults aged 65+ with gynecological cancer who are on chemotherapy. About 74 participants will do these exercises to see if they help with chemotherapy sid…
Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Can video calls replace clinic visits for palliative care?
Symptom relief Not yet recruitingThis study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…
Sponsor: Al Al Bayt University, Jordan • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New radiation method aims to spare anal canal, cut hemorrhoid misery in cervical cancer patients
Symptom relief Not yet recruitingThis trial tests whether protecting the anal canal during pelvic radiation can reduce hemorrhoid-related symptoms like pain, bleeding, and discomfort in cervical cancer patients. 300 women who had a hysterectomy and need radiation will be randomly assigned to standard radiation o…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Which hysterectomy is better? new trial aims to find out
Symptom relief Not yet recruitingThis study compares total laparoscopic hysterectomy (removing the whole uterus including the cervix) with subtotal laparoscopic hysterectomy (keeping the cervix) in 500 women with benign conditions like fibroids or endometriosis. The main goal is to see which surgery leads to bet…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Symptom relief
Last updated Jun 26, 2026 13:41 UTC
-
New survey aims to better understand ovarian cancer Patients' daily lives
Knowledge-focused Not yet recruitingThis study is testing a new questionnaire (called the QLQ-OV39) to see how well it measures quality of life in people with ovarian cancer. About 50 adults with early or advanced ovarian cancer will fill out the questionnaire and give feedback. The goal is to make sure the questio…
Sponsor: Helios University Hospital Wuppertal • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study aims to slash cervical cancer deaths in HIV-positive women
Knowledge-focused Not yet recruitingThis study tests better ways to screen and treat cervical cancer in women living with HIV in Kenya, who face a much higher risk. Researchers will use HPV self-testing, care navigators, and a mobile app to help more women get diagnosed and treated. The goal is to find strategies t…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Your gut bacteria may hold the key to whether immunotherapy works
Knowledge-focused Not yet recruitingResearchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Video education may boost informed genetic testing choices in cancer patients
Knowledge-focused Not yet recruitingThis study looks at whether an educational video can help people with certain cancers make informed choices about genetic testing. Participants will take a survey, watch a short video, and then take another survey to see if their knowledge and attitudes changed. The goal is to se…
Sponsor: Rachel Miller • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Can ultrasound sharpen the surgical map for ovarian cancer near the liver?
Knowledge-focused Not yet recruitingThis study tests whether a standardized ultrasound approach can reliably classify how ovarian cancer involves the liver area before surgery. Researchers will compare ultrasound images with what surgeons actually find during operations, using tissue samples as an extra check when …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study aims to boost cervical cancer screening for women with HIV
Knowledge-focused Not yet recruitingThis study looks at how to make cervical cancer screening easier for women with HIV, who are at higher risk for this cancer. Researchers will talk to patients and doctors to find out what gets in the way of screening and follow-up care. They will also explore using HPV self-testi…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can tumor markers guide future ovarian cancer treatments?
Knowledge-focused Not yet recruitingThis study examines tumor samples from 320 Latin American women with advanced ovarian, fallopian tube, or peritoneal cancer to describe the presence of certain markers (FRα, HER2, PD-L1, HRD, and BRCA). Researchers will collect medical history and test archived tumor tissue to se…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Blood test may flag cervical cancer return after surgery
Knowledge-focused Not yet recruitingThis study is testing whether a simple blood test that detects HPV DNA from tumor cells can help predict if cervical cancer will come back after surgery. Researchers will collect blood samples before surgery and at two time points afterward from about 580 patients with early-stag…
Sponsor: Anhui Provincial Hospital • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can big data improve safety in gynecologic surgery?
Knowledge-focused Not yet recruitingThis study is a large registry that will collect detailed information from thousands of women undergoing surgery for non-cancerous gynecologic conditions like fibroids, endometriosis, and ovarian cysts. The goal is to track surgical techniques, complications, and recovery in real…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can a text message and a Mail-In kit help prevent cervical cancer in women with HIV?
Knowledge-focused Not yet recruitingThis study explores whether a text-message education program and a mail-in HPV self-sampling kit can help women living with HIV who are overdue for cervical cancer screening get tested. Researchers will enroll 130 women and healthcare providers to see if the approach is practical…
Sponsor: Daisy Le • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
Knowledge-focused Not yet recruitingThis study aims to create new laboratory models of ovarian cancer that no longer respond to standard platinum-based chemotherapy or PARP inhibitors. Researchers will take tumor tissue from patients with resistant disease and grow it in mice and in the lab to mimic real clinical c…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Can a website empower endometrial cancer patients?
Knowledge-focused Not yet recruitingThis study aims to develop an online educational tool for women diagnosed with endometrial cancer. Participants will use a website to access educational content, complete surveys, and provide feedback on its usability. The goal is to create a resource that can be made widely avai…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New program aims to make cancer surgery safer for seniors
Knowledge-focused Not yet recruitingThis study looks at how a special program, called the Geriatric Surgery Verification Program, works at the James Cancer Hospital. The program helps doctors and nurses better care for patients aged 65 and older who need cancer surgery. It includes checking for age-related issues l…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Artificial intelligence may predict ovarian cancer recurrence — a large study puts it to the test
Knowledge-focused Not yet recruitingThis study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that for…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase 2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Can we predict brain fog in older women fighting ovarian cancer?
Knowledge-focused Not yet recruitingThis study follows women aged 70 and older with ovarian cancer to understand why some experience cognitive decline or delirium during treatment. Researchers will track memory, thinking skills, frailty, and quality of life over 12 months, and analyze blood samples for markers of b…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
HIV and cancer: study seeks to uncover hidden risk factors
Knowledge-focused Not yet recruitingThis study looks at how certain cancers develop in people with HIV and what factors might increase their risk. Researchers will analyze medical data from 1,000 HIV-positive adults to track which types of cancer occur most often and why. The goal is to improve early detection and …
Sponsor: Shenzhen Third People's Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Hidden risks: thickened uterine lining in asymptomatic women under the microscope
Knowledge-focused Not yet recruitingThis study looks at postmenopausal women who have a thickened uterine lining (endometrium) found by chance but have no symptoms like bleeding. Researchers will use a tiny camera (hysteroscopy) to view the lining and take tissue samples to compare the camera findings with lab resu…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
AI could outshine standard tumor measurements to predict survival
Knowledge-focused Not yet recruitingThis study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Your voice in the tumor board: study tests if patient reports lead to better cancer treatment
Knowledge-focused Not yet recruitingThis study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood test may spot returning cervical cancer before symptoms appear
Knowledge-focused Not yet recruitingThis study looks at whether pieces of tumor DNA and HPV DNA circulating in the blood can predict if cervical cancer will return after successful first-line treatment. Researchers will collect blood samples over time from 60 patients whose cancer has gone into complete remission. …
Sponsor: Zhejiang Cancer Hospital • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can storytelling and support groups break the stigma around cancer in rwanda?
Knowledge-focused Not yet recruitingThis study looks at how common stigma is for breast and cervical cancer patients, caregivers, and community health workers in Rwanda. It also tests a program called RISE that includes resilience training, support groups, and videos of cancer survivors to see if it can reduce stig…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a simple WhatsApp message save lives? chile tests new screening nudge
Knowledge-focused Not yet recruitingThis study will send different types of WhatsApp messages to 235,000 people in Chile who are due for cancer or chronic disease screenings. Researchers want to see if the way a message is worded (basic, risk-focused, or peace-of-mind) and whether it mentions one test or both tests…
Sponsor: University of Chile • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may spare some women from radiation after endometrial cancer surgery
Knowledge-focused Not yet recruitingThis study looks at whether a blood test that detects tumor DNA can help decide if women with early-stage endometrial cancer need radiation after surgery. About 1,010 women will be followed for two years. Those with a negative blood test may safely skip radiation, while others re…
Sponsor: Natera, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase 1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New digital tool aims to boost fertility awareness in cancer patients
Knowledge-focused Not yet recruitingThis study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receivin…
Sponsor: Biruni University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Doctors' teamwork under the microscope: can better meetings lead to better cancer care?
Knowledge-focused Not yet recruitingThis study looks at how doctors in tumor board meetings work together when discussing ovarian and uterine cancer cases. About 400 physicians will fill out surveys after each meeting to measure things like communication, teamwork, and decision-making. The goal is to understand wha…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New study hopes to catch cervical cancer recurrence earlier with HPV testing
Knowledge-focused Not yet recruitingThis study will follow 100 people with advanced cervical cancer who are getting radiation and chemo. Researchers want to see if checking for HPV and other markers in the blood and cervix can better predict if the cancer will come back. The goal is to find recurrences earlier and …
Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Web lessons aim to bust HPV test fears
Knowledge-focused Not yet recruitingThis study looks at whether a web-based education program can improve women's attitudes and beliefs about HPV testing, which is key for preventing cervical cancer. About 120 women aged 18-60 will take part, with half receiving the online education and the other half getting stand…
Sponsor: Sakarya University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
No-Scar surgery for endometrial cancer? new study tests vNOTES against standard laparoscopy
Knowledge-focused Not yet recruitingThis study compares two minimally invasive surgical methods for early-stage endometrial cancer: standard laparoscopy (small abdominal cuts) and vNOTES (surgery through the vagina with no visible scars). Researchers will enroll 160 women to see how well each method finds sentinel …
Sponsor: Cukurova University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Caregiver stress under the microscope: new study targets gynecologic cancer support
Knowledge-focused Not yet recruitingThis study follows 250 gynecologic cancer patients and their informal caregivers over 6 months. Researchers will use surveys to track caregiver distress and unmet needs. The goal is to understand what caregivers go through and find ways to better support them.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New dye technique could spare ovarian cancer patients from invasive surgery
Knowledge-focused Not yet recruitingThis study tests whether a dye called indocyanine green can help surgeons find cancer spread in early ovarian cancer. About 30 women will receive the dye during surgery to see if it can identify affected lymph nodes. If it works, it may reduce the need for removing many lymph nod…
Sponsor: Başakşehir Çam & Sakura City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Does breakfast change how chemo works? new study investigates
Knowledge-focused Not yet recruitingThis early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…
Phase 1 • Sponsor: Health Hope Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Could your daily urine predict uterine cancer?
Knowledge-focused Not yet recruitingThis study will ask 50 people aged 35 and older with abnormal uterine bleeding to collect daily urine samples and track their bleeding at home for several months. Researchers will use a home monitor to measure hormone levels and see if certain patterns are linked to uterine cance…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tests LASMAR score to improve fibroid surgery planning
Knowledge-focused Not yet recruitingThis study looks at whether the LASMAR scoring system can predict how well hysteroscopic myomectomy works for women with submucous fibroids. Researchers will check if the score matches surgery time, number of sessions, fluid use, and complications. The goal is to help doctors pla…
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New radiation monitor aims to catch errors during cancer treatment
Knowledge-focused Not yet recruitingThis study tests a plastic scintillation detector that can monitor radiation dose and source position in real time during brachytherapy for prostate and gynecologic cancers. The goal is to see if the device can be used without disrupting the treatment workflow. If it works, it co…
Sponsor: CISSS de Chaudière-Appalaches • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New HPV test could save lives of women with HIV
Knowledge-focused Not yet recruitingThis study looks at better ways to screen for HPV and prevent cervical cancer in women living with HIV. Researchers will test a new method that identifies specific HPV types and viral load. The goal is to see if this approach is practical for a larger future study. About 750 wome…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Blood test may help match cancer patients to best drugs
Knowledge-focused Not yet recruitingThis study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Education program aims to boost cancer screening in blind women
Knowledge-focused Not yet recruitingThis study tests whether a special education program can increase breast and cervical cancer screening among visually impaired women. About 74 women over age 40 will receive training on cancer risks and how to schedule screenings. Researchers will check if screening rates and kno…
Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
HPV-Positive pelvic cancer: study probes hidden toll on sex life
Knowledge-focused Not yet recruitingThis study follows 42 women with HPV-positive pelvic cancer (cervix, vagina, vulva, or anus) to understand how radiotherapy, with or without surgery, affects their sexual quality of life. Participants complete questionnaires about sexual function and emotional distress over time.…
Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Keyhole vs. open surgery: which is better for hysterectomy in Low-Resource areas?
Knowledge-focused Not yet recruitingThis study compares laparoscopic (keyhole) hysterectomy to traditional open abdominal hysterectomy in women aged 35-65 with benign gynecologic conditions. The main goal is to see which approach leads to a shorter hospital stay. The trial takes place in a low-resource setting, whe…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could nighttime chemo hours ease cancer care? survey seeks patient views
Knowledge-focused Not yet recruitingThis study uses an anonymous online survey to ask 200 women with gynecologic cancers whether they would be interested in receiving long chemotherapy infusions at night instead of during the day. The goal is to understand patient preferences and potential barriers. No treatment is…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Scientists hunt for biological clues to Cancer-Related anxiety and depression
Knowledge-focused Not yet recruitingThis study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can a bioreactor predict ovarian cancer chemo success?
Knowledge-focused Not yet recruitingThis study aims to see if a special device called a U-Cup bioreactor can predict how well standard chemotherapy will work in women with high-grade ovarian cancer. Researchers will take tumor samples from 120 patients before treatment and test them in the lab. The goal is to find …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict which cancer patients struggle most with eating
Knowledge-focused Not yet recruitingThis study looks at how cancer and its treatments change the way people experience food, including taste, mouth health, and overall eating pleasure. Researchers will ask 180 adults with different cancers to fill out a detailed questionnaire about their eating habits and feelings.…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Will removing fallopian tubes bring on menopause earlier? new study aims to find out
Knowledge-focused Not yet recruitingThis study follows 2100 women under 55 who had a hysterectomy, some with fallopian tube removal and some without. Researchers want to see if removing the tubes leads to earlier menopause. Participants will collect a few drops of blood at home and answer online questionnaires twic…
Sponsor: Umeå University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study aims to improve ovarian cancer surgery planning
Knowledge-focused Not yet recruitingThis study looks at how well different methods—imaging, a small camera surgery (laparoscopy), and open surgery (laparotomy)—agree on whether an ovarian mass can be completely removed. It will involve 28 women with primary ovarian cancer. The goal is to see if less invasive method…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Study aims to find best surgery to preserve fertility in cervical cancer patients
Knowledge-focused Not yet recruitingThis study reviews past research and hospital data to compare three types of fertility-sparing surgeries for cervical adenocarcinoma: conization, simple trachelectomy, and radical trachelectomy. The goal is to see which offers the best balance between controlling cancer and allow…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Ultrasound study to reveal hidden clues in Women's cancers
Knowledge-focused Not yet recruitingThis study uses a special 3D ultrasound to look at blood flow inside cervical and ovarian tumors. Researchers want to see if blood flow patterns can help tell the difference between cancer and pre-cancer, and if they can predict how well patients will do over time. About 100 adul…
Sponsor: Far Eastern Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Blood test may spot cancer recurrence months before scans
Knowledge-focused Not yet recruitingThis study is testing a new blood test that looks for tiny bits of cancer DNA (called minimal residual disease or MRD) in patients with endometrial or cervical cancer. The goal is to see if this test can find cancer coming back earlier than standard scans or exams. About 600 part…
Sponsor: Asan Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists hunt for biomarkers to personalize endometrial cancer immunotherapy
Knowledge-focused Not yet recruitingThis study will analyze tumor samples from 50 women with advanced or recurrent endometrial cancer to find biological markers that predict whether immunotherapy will work. Researchers will examine the tumor's DNA, epigenetics, and surrounding environment. The goal is to better und…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Protein clue may predict ovarian cancer outcomes
Knowledge-focused Not yet recruitingThis study looks at a protein called DHODH in tissue from 72 women with a type of ovarian cancer. Researchers want to see if the amount of this protein can help predict how well chemotherapy works and how long patients live. The goal is to better understand the disease, not to te…
Sponsor: Heba Ahmed Mohamed • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Hidden inherited genes in endometrial cancer: a new study investigates
Knowledge-focused Not yet recruitingThis study will test 20 people with endometrial cancer who also have a BRCA mutation in their tumor. Researchers will look for inherited (germline) gene changes using a blood test. The goal is to better understand genetic risks in this type of cancer. No treatment is given; it is…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Can a simple ultrasound predict cancer after molar pregnancy?
Knowledge-focused Not yet recruitingThis study will use Doppler ultrasound to measure blood flow in the uterine artery before and after removing a molar pregnancy. The goal is to see if these measurements can predict which patients will develop persistent gestational trophoblastic neoplasia, a type of cancer. Resea…
Sponsor: Minia University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Eye test for surgeons: can they spot cancer clues?
Knowledge-focused Not yet recruitingThis study checks if surgeons can tell key details about ovarian cancer by looking at images from a camera inside the belly. About 70-80 surgeons will review pictures from 19 patients and guess the cancer type and growth pattern. The goal is to see if visual clues can help plan t…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
AI takes on tough cancer decisions for Moms-to-Be
Knowledge-focused Not yet recruitingThis study will test whether an AI system can help doctors make better treatment decisions for pregnant women with cervical cancer. Researchers will compare the AI's recommendations to those from a real team of experts and from junior doctors. The goal is to see if the AI can pro…
Sponsor: Obstetrics & Gynecology Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Gene test could help young women with uterine cancer preserve fertility
Knowledge-focused Not yet recruitingThis study looks at 100 women aged 18-45 with early-stage endometrial cancer who want to preserve their fertility. Researchers will analyze the tumor's molecular subtype (based on gene testing) to see how it affects response to hormone therapy and recurrence rates. The goal is to…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Could ozone therapy soothe pelvic pain by changing gut bacteria?
Knowledge-focused Not yet recruitingThis study looks at 38 women who had pelvic side effects (like pain in the rectum, bladder, or vagina) after radiation or chemotherapy for gynecological cancers. Researchers will compare their gut bacteria to healthy controls and see if rectal ozone therapy changes the microbiome…
Sponsor: Bernardino Clavo, MD, PhD • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New study aims to catch ovarian cancer spread earlier with deeper tissue sampling
Knowledge-focused Not yet recruitingThis study tests whether removing a larger piece of the pelvic lining during surgery can find tiny cancer deposits that standard biopsies might miss. About 390 adults with early-stage ovarian or fallopian tube cancer will undergo this procedure. The goal is to improve staging acc…
Sponsor: Ospedale Santa Croce-Carle Cuneo • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
One surgery, two goals: can removing fibroids and retrieving eggs together boost IVF success?
Knowledge-focused Not yet recruitingThis pilot study will test whether it is safe and effective to remove uterine fibroids and retrieve eggs in a single surgical step for infertile women aged 18–45. The researchers will track pregnancy, miscarriage, and live birth rates after frozen embryo transfer. Only 20 women w…
Sponsor: San Carlo Public Hospital, Potenza, Italy • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Blood test after surgery could spot hidden cancer cells
Knowledge-focused Not yet recruitingThis study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Could CT scans replace MRI for cervical cancer radiation? major study launches
Knowledge-focused Not yet recruitingThis study looks at whether using CT scans instead of MRI for planning brachytherapy (internal radiation) can work just as well for locally advanced cervical cancer. About 1,200 participants will receive standard treatment, and researchers will track tumor control and side effect…
Sponsor: Homi Bhabha Cancer Hospital & Research Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Rare cervical cancer under the microscope: new study aims to unlock its secrets
Knowledge-focused Not yet recruitingThis study focuses on a rare and aggressive type of cervical cancer called large cell neuroendocrine carcinoma (LCNEC). Researchers will look back at medical records and follow 200 patients over time to understand the disease's behavior and what factors affect survival. The goal …
Sponsor: Lili • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Simple Pre-Surgery steps could boost stoma Patients' quality of life
Knowledge-focused Not yet recruitingThis study will follow 100 people who need a stoma (an opening in the belly to pass stool) after surgery. Some will have their stoma site marked and get education before surgery, while others will not. The goal is to see if these steps improve quality of life and reduce problems …
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New pelotte device aims to improve temperature accuracy in cancer heat therapy
Knowledge-focused Not yet recruitingThis study tests whether a new device called a pelotte can measure vaginal temperature more accurately during deep hyperthermia (heat therapy) for gynecologic cancer. Twenty-seven women receiving radiation plus heat therapy will have their temperature measured with both the pelot…
Sponsor: Dr. G.H. (Henrike) Westerveld • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
AI tool could make fibroid treatment more precise
Knowledge-focused Not yet recruitingThis study tests a new AI-powered software that helps doctors see, in real time, how well a minimally invasive fibroid treatment (uterine artery embolization) is working. The goal is to make the procedure more accurate and consistent. The study will involve 250 women with symptom…
Sponsor: Emanuele Barabino • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC